MX2020007406A - Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. - Google Patents

Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.

Info

Publication number
MX2020007406A
MX2020007406A MX2020007406A MX2020007406A MX2020007406A MX 2020007406 A MX2020007406 A MX 2020007406A MX 2020007406 A MX2020007406 A MX 2020007406A MX 2020007406 A MX2020007406 A MX 2020007406A MX 2020007406 A MX2020007406 A MX 2020007406A
Authority
MX
Mexico
Prior art keywords
antibody
antigen
binding fragment
pharmaceutical use
drug
Prior art date
Application number
MX2020007406A
Other languages
English (en)
Inventor
Weikang Tao
Lei Zhang
Qiyue Hu
Xiaoling Gu
Jiahua Jiang
Jinming Gu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020007406A publication Critical patent/MX2020007406A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Un novedoso anticuerpo contra PD-L1, un fragmento de union al antigeno del mismo, y un uso farmaceutico de los mismos; un anticuerpo humanizado que comprende una CDR del anticuerpo contra PD-L1, una composicion farmaceutica que comprende el anticuerpo contra PD-L1 y el fragmento de union al antigeno del mismo, y un uso del anticuerpo contra PD-L1 como un farmaco; y un uso de un anticuerpo contra PD-L1 humanizado en la preparacion de un farmaco para tratar enfermedades o trastornos asociados con PD-L1.
MX2020007406A 2018-01-10 2019-01-09 Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. MX2020007406A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810023267 2018-01-10
PCT/CN2019/070982 WO2019137397A1 (zh) 2018-01-10 2019-01-09 Pd-l1抗体、其抗原结合片段及医药用途

Publications (1)

Publication Number Publication Date
MX2020007406A true MX2020007406A (es) 2020-09-14

Family

ID=67219311

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007406A MX2020007406A (es) 2018-01-10 2019-01-09 Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.

Country Status (12)

Country Link
US (1) US11359021B2 (es)
EP (1) EP3741777A4 (es)
JP (1) JP2021510078A (es)
KR (1) KR20200108306A (es)
CN (1) CN111278861B (es)
AU (1) AU2019206958A1 (es)
BR (1) BR112020013475A2 (es)
CA (1) CA3087105A1 (es)
MX (1) MX2020007406A (es)
TW (1) TWI717678B (es)
WO (1) WO2019137397A1 (es)
ZA (1) ZA202004907B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6983371B2 (ja) * 2015-11-17 2021-12-17 スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
CN110760517B (zh) * 2019-10-09 2022-04-29 天津大学 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用
WO2022121846A1 (zh) * 2020-12-08 2022-06-16 博际生物医药科技(杭州)有限公司 Pd-l1抗体及其应用
TWI789679B (zh) * 2021-01-12 2023-01-11 大陸商江蘇先聲藥業有限公司 抗人程序性死亡配體-1（pd-l1）的抗體及其用途
CN115521378B (zh) * 2021-07-23 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-l1抗体及其用途
TW202317640A (zh) * 2021-09-24 2023-05-01 大陸商廣東菲鵬製藥股份有限公司 一種抗人pd-l1人源化抗體或其抗原結合片段及其應用
CN115925937A (zh) * 2022-08-05 2023-04-07 赛灵药业科技集团股份有限公司北京分公司 一种抗体或其片段及其制药用途
CN115785269B (zh) * 2022-11-01 2023-09-22 四川大学 抗pd-l1的抗体及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
CN104356236B (zh) * 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CN101104640A (zh) 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
AU2009296392B2 (en) * 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
PE20120341A1 (es) * 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
KR101573109B1 (ko) * 2009-11-24 2015-12-01 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CN115093480A (zh) 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
ES2848052T3 (es) 2012-08-03 2021-08-05 Dana Farber Cancer Inst Inc Anticuerpos de unión dual anti-PD-L1 y PD-L2 de agente individual y métodos de uso
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
RU2701378C2 (ru) 2013-03-15 2019-09-26 Дженентек, Инк. Биомаркеры и способы лечения связанных с pd-1 и pd-l1 состояний
EP3003282A1 (en) 2013-06-03 2016-04-13 Novartis AG Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
MY175472A (en) 2013-09-27 2020-06-29 Genentech Inc Anti-pdl1 antibody formulations
RU2722212C9 (ru) * 2014-08-05 2020-07-23 СиБи ТЕРЕПЬЮТИКС, ИНК. Анти-pd-l1 антитела
CN105777906B (zh) 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CA2978942A1 (en) * 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
CN106243225B (zh) * 2015-06-11 2021-01-19 智翔（上海）医药科技有限公司 新型抗-pd-l1抗体
JP6983371B2 (ja) * 2015-11-17 2021-12-17 スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
CN107216389B (zh) * 2016-03-18 2022-03-29 和迈生物科技有限公司 抗pd-l1纳米抗体及其编码序列和用途
EP3455257B1 (en) 2016-05-09 2021-09-22 IGM Biosciences Inc. Anti-pd-l1 antibodies
CN106699891B (zh) * 2017-01-25 2019-04-09 北京天广实生物技术股份有限公司 一种抗pd-l1抗体、其药物组合物及其用途
CN107365383B (zh) * 2017-07-12 2019-04-30 苏州大学附属第一医院 一种人源化抗人pd-1单克隆抗体及其制备方法、用途与药物
WO2019129136A1 (zh) * 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途

Also Published As

Publication number Publication date
US11359021B2 (en) 2022-06-14
WO2019137397A1 (zh) 2019-07-18
RU2020124261A (ru) 2022-01-25
RU2020124261A3 (es) 2022-01-25
CN111278861A (zh) 2020-06-12
KR20200108306A (ko) 2020-09-17
BR112020013475A2 (pt) 2020-12-08
ZA202004907B (en) 2022-10-26
US20200339692A1 (en) 2020-10-29
EP3741777A4 (en) 2021-10-13
TWI717678B (zh) 2021-02-01
TW201930360A (zh) 2019-08-01
JP2021510078A (ja) 2021-04-15
CA3087105A1 (en) 2019-07-18
EP3741777A1 (en) 2020-11-25
CN111278861B (zh) 2022-05-27
AU2019206958A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
MY184154A (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MX2021011489A (es) Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
MX2021005396A (es) Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX2017012965A (es) Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo.
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
MX2021009041A (es) Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2019014375A (es) Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2021002531A (es) Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
MX2021004226A (es) Terapia combinada contra el cáncer.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
MX2021003168A (es) Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico.
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.